NCT01648010View on ClinicalTrials.gov

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Carcinoma of Urinary Bladder, Invasive
Interventions
DEVICE

TC-3 gel

One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.

DEVICE

TC-3 gel mixed with Mitomycin C (MMC)

One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter

Trial Locations (3)

Unknown

Barzilai Hospital, Ashkelon

Wolfson, Holon

Beilinson, Petah Tikva

All Listed Sponsors
lead

UroGen Pharma Ltd.

INDUSTRY

NCT01648010 - Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter